Neola Medical AB (publ) (STO:NEOLA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 87.30M -58.5% |
| Revenue (ttm) | 8.28M -18.1% |
| Net Income | -11.02M |
| EPS | -0.14 |
| Shares Out | 77.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44 |
| Average Volume | 27,787 |
| Open | 1.130 |
| Previous Close | 1.120 |
| Day's Range | 1.130 - 1.130 |
| 52-Week Range | 0.602 - 3.040 |
| Beta | 1.57 |
| RSI | 60.35 |
| Earnings Date | Apr 21, 2026 |
About Neola Medical AB
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola ... [Read more]
Financial Performance
In 2025, Neola Medical AB's revenue was 8.28 million, a decrease of -18.13% compared to the previous year's 10.12 million. Losses were -11.02 million, 9.52% more than in 2024.
Financial StatementsNews
Neola Medical AB Earnings Call Transcript: Q4 2025
Entered clinical phase in 2025, secured SEK 20M in financing, and expanded IP portfolio with seven new patents. Clinical pilot in Sweden nears completion, with U.S. and European market launches targeted next. Cash reserves at SEK 60M; cost efficiency remains a focus.
Neola Medical AB Earnings Call Transcript: Q2 2025
Key milestones achieved in clinical and regulatory progress, including Swedish pilot study and U.S. study preparations. Financial position strengthened by SEK 20 million share issue and new patents granted in Europe and China. Strong market focus on U.S. and ongoing IP expansion.
Neola Medical AB Earnings Call Transcript: Q4 2024
2024 saw a strategic shift to clinical validation, with key regulatory and technical milestones achieved. The company is preparing for a Swedish pilot study in H1 2025, followed by a pivotal U.S. study, while maintaining cost control and strong shareholder support.
Neola Medical AB Earnings Call Transcript: Q3 2024
Advanced to clinical validation phase, secured key patents, and maintained strong cost control while preparing for pivotal U.S. clinical studies. Revenue growth is expected from disposables, with a solid cash position supporting ongoing operations.
Neola Medical AB Earnings Call Transcript: Q2 2024
Key milestones achieved in Q2 2024 include clinical validation progress, U.S. subsidiary setup, and strengthened financials. Pivotal U.S. clinical study is planned for H1 2025, with market launch targeted for late 2025 or early 2026.